These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33808271)

  • 1. PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
    Jørgensen CLT; Larsson AM; Forsare C; Aaltonen K; Jansson S; Bradshaw R; Bendahl PO; Rydén L
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression in metastatic breast cancer-patterns in primary tumors and metastatic tissue with prognostic potential.
    Tutzauer J; Larsson AM; Aaltonen K; Bergenfelz C; Bendahl PO; Rydén L
    Front Mol Biosci; 2023; 10():1343979. PubMed ID: 38449790
    [No Abstract]   [Full Text] [Related]  

  • 3. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
    Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
    Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
    Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
    Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
    Kimbung S; Kovács A; Danielsson A; Bendahl PO; Lövgren K; Frostvik Stolt M; Tobin NP; Lindström L; Bergh J; Einbeigi Z; Fernö M; Hatschek T; Hedenfalk I
    Oncotarget; 2015 Oct; 6(32):33306-18. PubMed ID: 26375671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
    Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():707. PubMed ID: 31448227
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
    BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
    Liu MC; Pitcher BN; Mardis ER; Davies SR; Friedman PN; Snider JE; Vickery TL; Reed JP; DeSchryver K; Singh B; Gradishar WJ; Perez EA; Martino S; Citron ML; Norton L; Winer EP; Hudis CA; Carey LA; Bernard PS; Nielsen TO; Perou CM; Ellis MJ; Barry WT
    NPJ Breast Cancer; 2016; 2():15023-. PubMed ID: 28691057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.
    Huang L; David O; Cabay RJ; Valyi-Nagy K; Macias V; Zhong R; Wenig B; Feldman L; Weichselbaum R; Spiotto MT
    Clin Cancer Res; 2019 Mar; 25(6):1795-1808. PubMed ID: 30573692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
    Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
    Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
    Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
    APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute assignment of breast cancer intrinsic molecular subtype.
    Paquet ER; Hallett MT
    J Natl Cancer Inst; 2015 Jan; 107(1):357. PubMed ID: 25479802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.